Cargando…
Pilot study of plasma creatine riboside as a potential biomarker for cervical cancer
This pilot study aimed primarily to evaluate plasma levels of a novel metabolite, creatine riboside, in patients with cervical cancer (discovery and validation cohorts, n = 11 for each) compared with non-cancer subjects (controls, n = 30). We found that the pre-treatment plasma creatine riboside lev...
Autores principales: | Oike, Takahiro, Osu, Naoto, Yoshimoto, Yuya, Obinata, Hideru, Yoshikawa, Kazuhiro, Harris, Curtis C., Ohno, Tatsuya |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10245246/ https://www.ncbi.nlm.nih.gov/pubmed/37292314 http://dx.doi.org/10.1016/j.heliyon.2023.e16684 |
Ejemplares similares
-
(64)Cu-ATSM Predicts Efficacy of Carbon Ion Radiotherapy Associated with Cellular Antioxidant Capacity
por: Nachankar, Ankita, et al.
Publicado: (2021) -
Creatine riboside is a cancer cell–derived metabolite associated with arginine auxotrophy
por: Parker, Amelia L., et al.
Publicado: (2022) -
Granulocyte‐colony stimulating factor‐producing uterine cervical cancer treated with chemoradiotherapy: A case report with mutation analysis and literature review
por: Shiba, Shintaro, et al.
Publicado: (2020) -
Mutation Analysis of Radioresistant Early-Stage Cervical Cancer
por: Oike, Tae, et al.
Publicado: (2021) -
High tumor mutational burden predicts worse prognosis for cervical cancer treated with radiotherapy
por: Ota, Norichika, et al.
Publicado: (2021)